Trial · NCT01446965

Vest Prevention of Early Sudden Death Trial and VEST Registry

NCT01446965, Not applicable, Completed, University of California, San Francisco; results first posted 2021-01-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Vest Prevention of Early Sudden Death Trial and VEST Registry. Trials, record NCT01446965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01446965

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Vest Prevention of Early Sudden Death Trial and VEST Registry
NCT number: NCT01446965
Status: Completed
Phases: Not applicable
Enrollment: 2,348 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Myocardial Infarction, Ventricular Dysfunction, Sudden Death, Ventricular Tachycardia, Ventricular Fibrillation
Interventions: wearable defibrillator
First posted: 2011-10-05
Last updated: 2021-01-20
Results first posted: 2021-01-20

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Sudden Death Mortality	three months after myocardial infarction	For witnessed deaths, sudden cardiac death will be defined as an unexpected non-traumatic, non-self-inflicted fatality in otherwise stable participants who die within one hour of the onset of the terminal symptoms. For unwitnessed deaths, participants will meet the definition of sudden death if they are found dead within 24 hours of being well, assuming there is no evidence of another cause of death during that time period.
Secondary	All Cause Mortality	three months after myocardial infarction	All deaths, due to any cause
Secondary	Compliance With Wearable Defibrillator Use	three months after myocardial infarction	daily wear time of the device

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Sudden Death Mortality	three months after myocardial infarction	A total of 2302 participants were included in the analyses.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	All Cause Mortality	three months after myocardial infarction		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Compliance With Wearable Defibrillator Use	three months after myocardial infarction	Conventional treatment participants did not wear defibrillator.	hours per day	MEDIAN

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Sudden Death Mortality	Wearable Defibrillator	25		Participants
Sudden Death Mortality	Conventional Treatment	19		Participants
All Cause Mortality	Wearable Defibrillator	48		Participants
All Cause Mortality	Conventional Treatment	38		Participants
Compliance With Wearable Defibrillator Use	Wearable Defibrillator	18	Inter-Quartile Range 3.8 to 22.7	hours per day

Source ClinicalTrials.gov

Participant flow20

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Randominization	STARTED	Wearable Defibrillator	1,554
Randominization	STARTED	Conventional Treatment	794
Randominization	COMPLETED	Wearable Defibrillator	1,524
Randominization	COMPLETED	Conventional Treatment	778
Randominization	NOT COMPLETED	Wearable Defibrillator	30
Randominization	NOT COMPLETED	Conventional Treatment	16
Participants Followed and Analyzed	STARTED	Wearable Defibrillator	1,524
Participants Followed and Analyzed	STARTED	Conventional Treatment	778
Participants Followed and Analyzed	Received WCD	Wearable Defibrillator	1,481
Participants Followed and Analyzed	Received WCD	Conventional Treatment	0

1 to 10 of 20Source ClinicalTrials.gov

See all 20 participant flow

Adverse events30

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Fatigue	General disorders	Wearable Defibrillator	510	1,524
other	Fatigue	General disorders	Conventional Treatment	274	778
other	Back pain	Musculoskeletal and connective tissue disorders	Wearable Defibrillator	283	1,524
other	Back pain	Musculoskeletal and connective tissue disorders	Conventional Treatment	137	778
other	Trouble sleeping	General disorders	Wearable Defibrillator	551	1,524
other	Trouble sleeping	General disorders	Conventional Treatment	264	778
other	Dizziness	General disorders	Wearable Defibrillator	344	1,524
other	Dizziness	General disorders	Conventional Treatment	166	778
other	Fainting	General disorders	Wearable Defibrillator	59	1,524
other	Fainting	General disorders	Conventional Treatment	36	778

1 to 10 of 30Source ClinicalTrials.gov

See all 30 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Wearable Defibrillator	48	1,524
Total, all-cause mortality	Conventional Treatment	38	778
Total, other adverse events	Wearable Defibrillator	1,421	1,524
Total, other adverse events	Conventional Treatment	714	778
Total, serious adverse events	Wearable Defibrillator	475	1,524
Total, serious adverse events	Conventional Treatment	253	778

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30280654	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Wearable Defibrillator vs Conventional Treatment: Sudden Death Mortality	Trial comparisons
Wearable Defibrillator vs Conventional Treatment: All Cause Mortality	Trial comparisons
Wearable Defibrillator vs Conventional Treatment: deaths from any cause	Trial comparisons
Wearable Defibrillator vs Conventional Treatment: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01446965

GET https://conductscience.org/api/trials/v1/NCT01446965/events?page=2

API reference For AI assistants